Overview
Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitisPhase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Fluticasone
Criteria
Inclusion Criteria:- Male and female subjects between ages of 18 to 60 in good health
- History of atopy for at least 2 years and positive skin prick test to ragweed allergen
Exclusion criteria:
- History of asthma treated with corticosteroids
- Smokers with a smoking history of > 10 pack/years or smoking in the past year
- History of chronic obstructive pulmonary disease
Other protocol-defined inclusion/exclusion criteria may apply